ISRCTN76612274已完成4 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre parallel group randomised controlled trial
niversity of Nottingham (UK)0 个研究点目标入组 108 人开始时间: 2010年5月28日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
- 2013 protocol in http://www.ncbi.nlm.nih.gov/pubmed/23302220 2. 2016 results in https://www.ncbi.nlm.nih.gov/pubmed/25765462
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 13/01/2011:
- •1) Male or Female patients aged 18-75 years able to give informed consent.
- •2) Patients should all have had a colonoscopy within the last 12 months to exclude microscopic or any inflammatory colitis. (If not, but they have had a negative colonoscopy within 5 years and symptoms are unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would be sufficient to exclude microscopic or any inflammatory colitis).
- •3) IBS-D Patients meeting Rome III criteria prior to screening phase.
- •4) Patients with =25% soft (score >4) and <25% hard (score 1 or 2) stools during the screening phase, as scored by the daily symptom and stool diary*.
- •5) Patients with an average stool frequency of 3 or more per day during the screening phase*.
- •6) Satisfactory completion of the daily stool and symptom diary during the screening phase at the discretion of the investigator.
- •7) Women of child bearing potential willing and able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as: implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.
- •*If inclusion criterion 4 and/or 5 is/are not met but the results are considered atypical (as observed from medical history and patient recall) then the patient can be re-screen on 1 occasion only.
- •Previous inclusion criteria:
- •1. IBS-D patients meeting Rome III criteria
- •2. Male or female patients aged 18 - 75 years
- •3. Able to give informed consent
排除标准
- •Current exclusion criteria as of 13/01/2011:
- •1) Women who are pregnant or breast feeding
- •2) Prior abdominal surgery which may cause bowel symptoms similar to IBS (note appendectomy and cholecystectomy will not be an exclusion)
- •3) Patients unable to stop anti-muscarinics, anti-spasmodics, high dose tricyclic antidepressants (i.e. above 50 mg/day), opiates / anti-diarrhoeal drugs*, NSAIDs (occasional over the counter use and topical formulations are allowed), long-term antibiotics, other anti-inflammatory drugs or 5-ASA containing drugs.
- •4) Patients on selective serotonin re-uptake inhibitors and low dose tricyclic antidepressants (i.e. up to 50 mg/day) for at least 3 months previous unwilling to remain on a stable dose for the duration of the trial.
- •5) Patients with other gastro-intestinal diseases including colitis and Crohn?s disease.
- •6) Patients with the following conditions: Renal impairment, severe hepatic impairment or salicylate hypersensitivity.
- •7) Patients currently participating in another trial or have been in a trial within the previous 3 months
- •8) Patients who in the opinion of the investigator are considered unsuitable due to inability to comply with instructions
- •9) Patients with serious concomitant diseases e.g. cardiovascular, respiratory, neurological etc.
- •*Loperamide is allowed as rescue medication through-out the trial, however if >2 doses / week are taken during the screening phase then they are not eligible, though they can be re-screened on 1 occasion only.
- •Previous exclusion criteria:
- •1. Women who are pregnancy or breast feeding or women of child bearing potential who are not willing to use medically acceptable forms of contraception during the study, (e.g. implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partners)
- •2. Prior abdominal surgery which may cause bowel symptoms similar to IBS (note appendectomy and cholecystectomy will not be an exclusion)
- •3. Patients unable to stop anti-diarrhoeal drugs, non-steriodal anti-inflammatory drugs (NSAIDs) (occasional over the counter use is allowed), other anti-inflammatory drugs (azathioprine or related drugs) or already taking 5-aminosalicylic acid (5-ASA) containing drugs.
- •4. Patients with other gastro-intestinal diseases including colitis and Crohn's disease
- •5. Patients with the following conditions: renal impairment, severe hepatic impairment or salicylate hypersensitivity
- •6. Patients currently participating in another trial or have been in a trial within the previous 3 months
- •7. Patients who in the opinion of the investigator are considered unsuitable due to inability to comply with instructions
研究者
相似试验
已完成
4 期
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)Irritable Bowel Syndrome With DiarrhoeaNCT01316718University of Nottingham108
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
已完成
不适用
Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs).Patients with rheumatoid arthritis with anemia taking NSAIDsJPRN-UMIN000005362Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine13
撤回
3 期
The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral UlcerOral UlcerCrohn's DiseaseNCT02769494Xijing Hospital of Digestive Diseases